Ca2+ channel antagonists and neuroprotection from cerebral ischemia

European Journal of Pharmacology

Volumn 363, Issue 1, 1998, Pages 1-15

  Kobayashi, Tsutomu ^a   Mori, Yasuo ^b  

^a Discov and Pharmacol Res Labs   (Japan)

^b NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

Ca2+ channel antagonist; Ischemia; Neuroprotection; Voltage dependent Ca2+ channel

Indexed keywords

CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT;

APOPTOSIS; BRAIN ISCHEMIA; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 84920304769     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00774-2     Document Type: Review

References (114)

1. 2+ current in rat aorta smooth muscle cells in primary culture. J. Physiol. 416:1989;141-160.
2. 2+ channels in isolated rat hypothalamic neurons. J. Physiol. 412:1989;181-195.
3. Allen G.S., Banghart S.B. Cerebral arterial spasm: Part 9. In vitro effects of nifedipine on serotonin-, phenylephrine-, and potassium-induced contractions of canine basilar and femoral arteries. Neurosurgery. 4:1979;37-42.
4. Alps B.J., Calder C., Hass W.K., Wilson A.D. The delayed post-ischemic treatment effects of nicardipine in a rat model of four vessel occlusion. Br. J. Pharmacol. 91:1987;312P.
5. Alps B.J., Calder C., Wilson A.D., McBean D.E., Armstrong J.M. Reduction by lifarizine of the neuronal damage induced by cerebral ischaemia in rodents. Br. J. Pharmacol. 115:1995;1439-1446.
6. Amagasa M., Ogawa A., Yoshimoto T. Effects of calcium and calcium antagonists against deprivation of glucose and oxygen in guinea pig hippocampal slices. Brain Res. 526:1990;1-7.
7. 2+ channel trigger secretion with different efficacies in chromaffin cells. Nature. 367:1994;72-76.
8. 2+ channel blocker, α-eudesmol, in rat focal ischemic brain injury. Jpn. J. Pharmacol. 73:1997;212P.
9. Astrup J., Siesjo B.K., Symon L. Thresholds in cerebral ischemia - theischemic penumbra. Stroke. 12:1981;723-725.
10. Barone F.C., Price W.J., Jakobsen P., Sheardown M.J., Feuerstein G. Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol. Biochem. Behav. 48:1994;77-85.
11. 2+ currents in central neurons and reduces the effects of focal ischemia in rats and mice. Stroke. 26:1995;1683-1689.
12. Bean B.P. Nitrendipine block of cardiac calcium channels: high-affinity binding to the inactivated state. Proc. Natl. Acad. Sci. U.S.A. 81:1984;6388-6392.
13. Bech-Hansen N.T., Naylor M.J., Maybaum T.A., Pearce W.G., Koop B., Fishman G.A., Mets M., Musarella M.A., Boycott K.M. Loss-of-function mutations in a calcium-channel alpha1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness. Nat. Genet. 19:1998;264-267.
14. Beck T., Nuglisch J., Sauer D., Bielenberg G.W., Mennel H.D., Rossberg C., Krieglstein J. Effects of flunarizine on postischemic blood flow, energy metabolism and neuronal damage in the rat brain. Eur. J. Pharmacol. 158:1988;271-274.
15. 2+ antagonist is neuroprotective in two models of cerebral ischaemia. Neuropharmacology. 32:1993;1249-1257.
16. Besson G., Bogousslavsky J. Medical treatment of acute ischemic stroke. J. Cardiovasc. Pharmacol. 18:1991;S6-S9. (suppl. 8).
17. 2+ channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia. J. Cereb. Blood Flow Metab. 14:1994;903-910.
18. 2+ antagonist with platelet-activating factor-antagonistic action, F-401, against ischemic brain damage. Arch. Int. Pharmacodyn. Ther. 327:1994;266-278.
19. Chen J., Graham S.H., Chan P.H., Lan J., Zhou R.L., Simon R.P. Bcl-2 is expressed in neurons that survive focal ischemia in the rat. Neuroreport. 6:1995;394-398.
20. Choi D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. TINS. 11:1988;465-469.
21. Chopp M., Li Y., Zhang Z.G., Freytag S.O. p53 Expression in brain after middle cerebral artery occlusion in the rat. Biochem. Biophys. Res. Commun. 182:1992;1201-1207.
22. Clozel J.P., Ertel E.A., Ertel S.I. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J. Hypertens. Suppl. 15:1997;S17-S25.
23. 2+ channel gene family. Circ. Res. 83:1998;103-109.
24. Crumrine R.C., Thomas A.L., Morgan P.F. Attenuation of p53 expression protects against focal ischemic damage in transgenic mice. J. Cereb. Blood Flow Metab. 14:1994;887-891.
25. Cullen J.P., Aldrete J.A., Jankovsky L., Romo-Salas F. Protective action of phenytoin in cerebral ischemia. Anesth. Analg. 58:1979;165-169.
26. Deisseroth K., Heist E.K., Tsien R.W. Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons. Nature. 392:1998;198-202.
27. 2+ channel and 5-HT receptor antagonist (S)-emopamil in cerebral ischemia. TIPS. 10:1989;215-217.
28. 2+ entry blocker, ameliorates ischemic brain damage in the rat. Anesthesiology. 64:1986;215-224.
29. Deshpande J.K., Siesjo B.K., Wieloch T. Calcium accumulation and neuronal damage in the rat hippocampus following cerebral ischemia. J. Cereb. Blood Flow Metab. 7:1987;89-95.
30. Dingledine R., McBain C.J., McNamara J.O. Excitatory amino acid receptors in epilepsy. Trends Pharmacol. Sci. 11:1990;334-338.
31. Fleckenstein A. History of calcium antagonists. Circ. Res. 52:1983;3-16. (suppl. I).
32. Franke C.L., Palm R., Dalby M., Schoonderwaldt H.C., Hantson L., Eriksson B., Lang-Jenssen L., Smakman J. Flunarizine in stroke treatment (FIST): a double-blind, placebo-controlled trial in Scandinavia and the Netherlands. Acta Neurol. Scand. 93:1996;56-60.
33. Gaur S., Newcomb R., Rivnay B., Bell J.R., Yamashiro D., Ramachandran J., Miljanich G.P. Calcium channel antagonist peptides define several components of transmitter release in the hippocampus. Neuropharmacology. 33:1994;1211-1219.
34. Ghosh A., Greenberg M.E. Calcium signalling in neurons: molecular mechanisms and cellular consequences. Science. 268:1995;239-247.
35. 2+ channels controlling presynaptic release of glutamate. Ann. New York Acad. Sci. 765:1995;210-229.
36. Goto K., Ishige A., Sekiguchi K., Iizuka S., Sugimoto A., Yuzurihara M., Aburada M., Hosoya E., Kogure K. Effects of cycloheximide on delayed neuronal death in rat hippocampus. Brain Res. 534:1990;299-302.
37. Gross R.A., Macdonald R.L. Barbiturates and nifedipine have different and selective effects on calcium curremts of mouse DRG neurons in culture: a possible basis for differing clinical actions. Neurology. 38:1988;443-451.
38. Hallmayer J., Hossmann K.A., Mies G. Low dose of barbiturates for prevention of hippocampal lesions after brief ischemic episodes. Acta Neuropath. (Berlin). 68:1985;27-31.
39. Hara H., Harada K., Sukamoto T. Chronological atrophy after transient middle cerebral artery occlusion in rats. Brain Res. 618:1993;251-260.
40. Hossmann K.A. Viability thresholds and the penumbra of focal ischemia. Ann. Neurol. 36:1994;557-565.
41. Hossmann K.A., Kleihues P. Reversibility of ischemic brain damage. Arch. Neurol. 29:1973;375-384.
42. Hunter A.J., Green A.E., Cross A.J. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? TINS. 16:1995;123-128.
43. Iizuka H., Sakatani K., Young W. Neural damage in the rat thalamus after cortical infarcts. Stroke. 21:1990;790-794.
44. 2+ channel blocker, reduces infarct volume following middle cerebral artery occlusion in rats. Jpn. J. Pharmacol. 71:1996;175P.
45. Johansen F.F., Jorgensen M.B., Diemer N.H. Ischemic CA-1 pyramidal cell loss is prevented by preischemic colchicine destruction of dentate gyrus granule cells. Brain Res. 377:1986;344-347.
46. 2+ entry blocker, NB-818, on delayed neuronal death in the ischemic gerbil hippocampus. Jpn. J. Pharmacol. 56:1991;279-286.
47. Kass I.S., Cottrell J.E., Chambers G. Magnesium and cobalt, not nimodipine, protect neurons against anoxic damage in the rat hippocampal slice. Anesthesiology. 69:1988;710-715.
48. Kawai K., Penix L.P., Kawahara N., Reutzler C.A., Klatzo I. Development of susceptibility to audiogenic seizures following cardiac arrest cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 15:1995;248-258.
49. Kikkawa K., Yamauchi R., Suzuki T., Banno K., Murata S., Tezuka T., Nagao T. Clentiazem improves cerebral ischemia induced by carotid artery occlusion of stroke-prone spontaneously hypertensive rats. Stroke. 25:1994;474-480.
50. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res. 239:1982;57-59.
51. i in rat cerebral synaptosomes and hippocampal neurons. Jpn. J. Pharmacol. 58:1992;417-425.
52. 2+ channels expressed in Xenopus oocytes. Eur. J. Pharmacol. 332:1997;313-320.
53. Koh J.Y., Cotman C.W. Programmed cell death: its possible contribution to neurotoxicity mediated by calcium channel antagonists. Brain Res. 587:1992;233-240.
54. Kuwaki T., Satoh H., Ono T., Shibayama F., Yamashita T., Nishimura T. Nilvadipine attenuates ischemic degradation of gerbil brain cytosckeletal proteins. Stroke. 20:1989;78-83.
55. Leslie S.W., Friedman M.B., Wilcox R.E., Elrod S.V. Acute and chronic effects of barbiturates on depolarization-induced calcium influx into rat synaptosomes. Brain Res. 185:1980;409-417.
56. 2+ channels as drug targets for the treatment of epilepsy or ischemic stroke. Neuropharmacology. 36:1997;107-113.
57. Linnik M.D., Zahos P., Geschwind M.D., Federoff H.J. Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke. 26:1995;1670-1674.
58. Lipton S.A. Calcium channel antagonists in the prevention of neurotoxicity. Adv. Pharmacol. 22:1991;271-297.
59. Lu Y.M., Frostl W., Dreessen J., Knopfel T. P-type calcium channels are blocked by the alkaloid daurisoline. Neuroreport. 5:1994;1489-1492.
60. Martinou J.C., Dubois-Dauphin M., Staple J.K., Rodriguez I., Frankowski H., Missotten M., Albertini P., Talabot D., Catsicas S., Pietra C.et al. Overexpression of BCL-2 in transgenic mice protects neurons from naturally occurring cell death and experimental ischemia. Neuron. 13:1994;1017-1030.
61. Meyer F.B. Calcium, neuronal hyperexcitability and ischemic injury. Brain Res. Brain Res. Rev. 14:1989;227-243.
62. 2+ channels are located on somata, dendrites, and a subpopulation of dendritic spines on live hippocampal pyramidal neurons. J. Neurosci. 14:1994;6815-6824.
63. 2+ channels by Ro 40-5967. Circ. Res. 75:1994;144-148.
64. 2+-channel blocker NS-638. Neurol. Res. 17:1995;353-360.
65. Mori Y., Mikala G., Varadi G., Kobayashi T., Koch S., Wakamori M., Schwartz A. Molecular pharmacology of voltage-dependent calcium channels. Jpn. J. Pharmacol. 72:1996;83-109.
66. Murphy T.H., Worley P.F., Baraban J.M. L-type voltage sensitive calcium channels mediate synaptic activation of immediate early genes. Neuron. 7:1991;625-635.
67. Nagasawa H., Kogure K. Exo-focal postischemic neuronal death in the rat brain. Brain Res. 524:1990;196-202.
68. Obrenovitch T.P., Richards D.A. Extracellular neurotransmitter changes in cerebral ischemia. Cerebrovasc. Brain Metab. Rev. 7:1995;55-73.
69. Okamoto M., Matsumoto M., Ohtsuki T., Taguchi A., Mikoshiba K., Yanagihara T., Kamada T. Internucleosomal DNA cleavage involved in ischemia-induced neuronal death. Biochem. Biophys. Res. Commun. 196:1993;1356-1362.
70. + channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur. J. Pharmacol. 332:1997;121-131.
71. Ousley A.H., Froehner S.C. An anti-peptide antibody specific for the class A calcium channel alpha 1 subunit labels mammalian neuromuscular junction. Proc. Natl. Acad. Sci. U.S.A. 91:1994;12263-12267.
72. 2+-mediated neuronal death in rat brain neuronal cultures by veratridine: protection by flunarizine. Mol. Pharmacol. 36:1989;525-531.
73. Perez-Reyes E., Cribbs L.L., Daud A., Lacerda A.E., Barclay J., Williamson M.P., Fox M., Rees M., Lee J.H. Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature. 391:1998;896-900.
74. Poignet H., Beaughard M., Lecoin G., Massingham R. Functional, behavioral, and histological changes induced by transient global cerebral ischemia in rats: effects of cinnarizine and flunarizine. J. Cereb. Blood Flow Metab. 9:1989;646-654.
75. 2+ channel antagonist omega conotoxin MVIIA is neuroprotective against hypoxic neurodegenaration in organotypic hippocampal-slice cultures. Stroke. 27:1996;2124-2130.
76. 2+ currents blocked by the spider toxin omega-Aga-IVA. Neuroreport. 5:1993;333-336.
77. Pulsinelli W.A., Brierley J.B., Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann. Neurol. 11:1982;491-498.
78. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci. 18:1995;57-58.
79. 2+ channel antagonist, NC-1100, spontaneously hypertensive rats. Eur. J. Pharmacol. 224:1992;109-115.
80. Saito I., Ueda Y., Sano K. Significance of vasospasm in the treatment of ruptured intracranial aneurysms. J. Neurosurg. 47:1977;412-419.
81. Sauter A., Rudin M., Wiederhold K.H., Hof R.P. Cerebrovascular, biochemical, and cytoprotective effects of isradipine in laboratory animals. Am. J. Med. 86:1989;134-146.
82. Sheardown M.J., Hansen A.J., Petersen V., Birn P., Judge M.E., Jakobsen P. The neuroprotective effect of NNC 09-0026, a new calcium channel blocker in global ischemia. J. Cereb. Blood Flow Metab. 13(Suppl. 1):1993;566.
83. Shigeno T., Yamasaki Y., Kato G., Kusaka K., Mima T., Takakura K., Graham D., Furukawa S. Reduction of delayed neuronal death by inhibition of protein synthesis. Neurosci. Lett. 120:1990;117-119.
84. 2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats. Br. J. Pharmacol. 115:1995;1359-1368.
85. 2+ antagonists than peripheral arteries. Stroke. 11:1980;261-266.
86. Siesjo B.K., Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. J. Cereb. Blood Flow Metab. 9:1989;127-140.
87. +] in the hippocampus during recovery from short-term, transient ischemia. J. Cereb. Blood Flow Metab. 12:1992;759-772.
88. Small D.L., Monette R., Mealing G., Buchan A.M., Morley P. Neuroprotective effects of omega-Aga-IVA against in vitro ischaemia in the rat hippocampal slice. Neuroreport. 6:1995;1617-1620.
89. Sohn R.S., Ferrendelli J.A. Anticonvulsant drug mechanisms. Phenytoin, phenobarbital, and ethosuximide and calcium flux in isolated presynaptic endings. Arch. Neurol. 33:1976;626-629.
90. 2+ channels. Trends Pharmacol. Sci. 16:1995;139-142.
91. Steen P.A., Newberg L.A., Milde J.H., Michenfelder J.D. Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischemia in the dog. J. Cereb. Blood Flow Metab. 3:1983;38-43.
92. Strom T.M., Nyakatura G., Apfelstedt-Sylla E., Hellebrand H., Lorenz B., Weber B.H., Wutz K., Gutwillinger N., Ruther K., Drescher B., Sauer C., Zrenner E., Meitinger T., Rosenthal A., Meindl A. An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness. Nat. Genet. 19:1998;260-263.
93. Szatkowski M., Attwell D. Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. TINS. 17:1994;359-365.
94. Szatkowski M., Barbour B., Attwell D. Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature. 348:1990;443-446.
95. Takahashi T., Momiyama A. Different types of calcium channels mediate central synaptic transmission. Nature. 366:1993;156-158.
96. Tamura A., Kirino T., Sano K., Takagi K., Oka H. Atrophy of ipsilateral substantia nigra following middle cerebral artery occlusion in the rat. Brain Res. 510:1990;154-157.
97. The American Nimodipine Study Group, 1992. Clinical trial of nimodipine in acute ischemic stroke. Stroke 23, 3-8.
98. Toni D., Frontoni M., Argentino C., Sacchetti M.L., De Michele M., Fieschi C. Update on calcium antagonists in cerebrovascular diseases. J. Cardiovasc. Pharmacol. 18:1991;S10-S14. (suppl. 8).
99. Triggle D.J. Calcium channel drugs: structure-function relationships and selectivity of action. J. Cardiovasc. Pharmacol. 18:1991;S1-S6. (suppl. 10).
100. Turner T.J., Adams M.E., Dunlap K. Calcium channels coupled to glutamate release identified by w-Aga-IVA. Science. 258:1992;310-313.
101. Twombly D.A., Yoshii M., Narahashi T. Mechanisms of calcium channel block by phenytoin. J. Pharmacol. Exp. Ther. 246:1988;189-195.
102. Tymianski M., Charlton M.P., Carlen P.L., Tator C.H. Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J. Neurosci. 13:1993;2085-2104.
103. Uematsu D., Greenberg J.H., Reivich M., Kobayashi S., Karp A. In vivo fluorometric measurement of changes in cytosolic free calcium from the cat cortex during anoxia. J. Cereb. Blood Flow Metab. 8:1988;367-374.
104. Valentino K., Newcomb R., Gadbois T., Singh T., Bowersox S., Bitner S., Justice A., Yamashiro D., Hoffman B.B., Ciaranello R., Miljanich G., Ramachandran J. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl. Acad. Sci. U.S.A. 90:1993;7894-7897.
105. 2+ antagonists nifedipine and nimodipine across the blood-brain barrier and their regional distribution in vivo. J. Cereb. Blood Flow Metab. 5:1985;459-460. (Suppl. 1).
106. 2+ blocker 2-amino-1-(2,5-dimethoxyphenyl)-5-trifluoromethyl benzimidazole (NS-649). Biorg. Med. Chem. Lett. 6:1996;245-248.
107. Wauquier A., Ashton D., Clincke G., Fransen J. Calcium entry blockers as cerebral protecting agents: comparative activity in tests of hypoxia and hyperexcitability. Jpn. J. Pharmacol. 38:1985;1-7.
108. 2+ channels at the base of major dendrites in hippocampal pyramidal neurons. Nature. 347:1990;281-284.
109. 2+ channel α1 subunit. Neuron. 9:1992;1099-1115.
110. Wieloch T., Lindvall O., Blomqvist P., Gage F.H. Evidence for amelioration of ischemic neuronal damage in the hippocampal formation by lesions of the perforant path. Neuronal. Res. 7:1985;24-26.
111. Wood N.I., Barone F.C., Benham C.D., Brown T.H., Campbell C.A., Cooper D.G., Evans M.L., Feuerstein G.Z., Hamilton T.C., Harries M.H., King P.D., Meakin J.E., Murkitt K.L., Patel S.R., Price W.J., Roberts J.C., Rothaul A.L., Samson N.A., Smith S.J., Hunter A.J. The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J. Cereb. Blood Flow Metab. 17:1997;421-429.
112. 2+ antagonist, KB-2796, on cerebral ischemic neuronal damage in rats. Gen. Pharmacol. 24:1993;1473-1480.
113. Yao L.P., Ding D.Y. Effect of nicardipine on somatosensory evoked potentials in patients with acute cerebral infarction. J. Neurol. Neurosurg. Psychiatry. 53:1990;844-846.
114. 2+ channel blockers. Brain Res. 642:1994;146-152.